Table 4.

Nonhematological adverse events grades 3 to 5 after BEAM/auto-SCT and FBC/allo-SCT

	Transplant recipients, n (%)
	BEAM/auto-SCT (n = 41)*		FBC/allo-SCT (n = 26)
Nausea	2/40	5	2/26	8
Vomiting	1/40	2	1/26	4
Diarrhea	4/40	10	3/26	12
Constipation	0/41	0	0/26	0
Mucositis/stomatitis	13/41	32	6/26	23
Cardiac arrhythmia	1/40	2	1/25	4
Cardiac general	1/41	2	0/26	0
Hemorrhage/bleeding	2/41	5	1/26	4
Renal/genitourinary	0/41	0	4/26	15
Neuropathy sensory	0/41	0	0/26	0
Mood alteration	0/41	0	1/26	4
Allergic reaction/hypersensitivity	0/40	0	0/26	0
Infections	13/41	32	10/26	38
Hepatotoxicity (other than VOD)	—	—	1/26	4
VOD	—	—	0/26	0

VOD, venous occlusive disease.

^*Seven patients randomized to allo-SCT are included.